Consistent with the functions of YAP/TAZ in contributing to tumor resistance against EGFR-TKI therapies, these proteins are also required for the elastic modulus-dependent response to lapatinib, an FDA-approved human epidermal growth factor receptor 2 (HER2)-targeted kinase inhibitor. This evidence concerns the gene YAP1 and neoplasm.